← Eichor
Condition: Mixed Phenotype Acute Leukemia Mpal Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Mixed Phenotype Acute Leukemia Mpal

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Phase 1 · 1 location(s) · Stanford University · NCT06551584Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Phase 4 · 5 location(s) · St. Jude Children's Research Hospital · NCT06289673CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relap
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04375631211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymph
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03128034Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06928662Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Phase 3 · 124 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05327894The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia T
Phase 1/Phase 2 · 183 location(s) · PedAL BCU, LLC · NCT04726241Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
Phase 2 · 1 location(s) · West Virginia University · NCT07222579Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or
Phase 2 · 6 location(s) · Orca Biosystems, Inc. · NCT07216443Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
Phase 2 · 4 location(s) · St. Jude Children's Research Hospital · NCT06390319211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Le
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03670966Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell
Phase 2 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07256210Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers
Phase 2 · 10 location(s) · Fred Hutchinson Cancer Center · NCT03779854HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921A Study of Revumenib and Mezigdomide in People With Leukemia
Phase 1/Phase 2 · 10 location(s) · Memorial Sloan Kettering Cancer Center · NCT07356154Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Phase 1/Phase 2 · 1 location(s) · University of Washington · NCT04797767Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/Phase 2 · 9 location(s) · Vironexis Biotherapeutics Inc. · NCT06533579Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Phase 1 · 3 location(s) · Meryx, Inc. · NCT04872478Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
Phase 2 · 1 location(s) · yuejun Liu · NCT07012447A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Phase 1/Phase 2 · 57 location(s) · Syndax Pharmaceuticals · NCT04065399Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06013423A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Phase 1 · 12 location(s) · Orca Biosystems, Inc. · NCT03802695Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute L
Phase 3 · 231 location(s) · Children's Oncology Group · NCT03959085
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.